{"url_path":"/sec/gyre/8-k/2026-07-16/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028716-index.html","accession_number":"0001140361-26-028716","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028716-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":326,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n \n\nOn July 10, 2026, the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1, 2026. Mr. Kirkby was also appointed to serve on the Compensation Committee of the Board and Dr. Weston was appointed to serve on the Audit Committee of the Board.\n\n \n\nMr. Kirkby and Dr. Weston will each receive an initial grant of stock options to purchase 40,000 shares of our common stock, vesting in equal monthly installments over three years, and will be entitled to receive cash compensation in accordance with the Company’s non-employee director compensation policy as generally described in the Company’s Definitive Proxy Statement filed on April 27, 2026. Mr. Kirkby and Dr. Weston are also entering into the Company’s standard form of indemnification agreement, a form of which was previously filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on October 30, 2023. Dr. Xiong previously entered into the Company’s standard form of indemnification agreement in connection with his appointment as the Company’s Chief Scientific Officer and will receive no additional compensation for his service on the Board.\n\n \n\nThere are no arrangements or understandings between any of Mr. Kirkby and Drs. Xiong and Weston and any other person pursuant to which such individual was appointed as director of the Company; there are no family relationships between any of Mr. Kirkby and Drs. Xiong and Weston and any director or executive officer of the Company; and none of Mr. Kirkby or Drs. Xiong and Weston are party to any transactions of the type that would require disclosure under Item 404(a) of Regulation S-K."}